Sentien Biotechnologies Names Richard Ganz as Executive Chairman

LEXINGTON, Mass. (PRWEB) May 15, 2020 Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, today announced the appointment of Richard Ganz as Executive Chairman. Mr. Ganz will continue to lead Sentien’s Board of Directors, a role…

Source link

Related posts

Structural and functional role of disulphide bonds and substrate binding residues of the human beta-galactoside alpha-2,3-sialyltransferase 1 (hST3Gal1)


Sperm pre-fertilization thermal environment shapes offspring phenotype and performance [RESEARCH ARTICLE]


Life in the flow: unique adaptations for feeding on drifting zooplankton in garden eels [RESEARCH ARTICLE]


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World